menu

Tag: asco 2022 conference

Junshi’s domestic Toripalimab’s significant results in...

Junshi’s domestic Toripalimab’s significant results in recurrent or metasta...

  • havensmith

Sermonix’s Lasofoxifene, a potent oral SERM, emerges as...

Sermonix’s Lasofoxifene, a potent oral SERM, emerges as a critical player i...

  • havensmith

Mimivax’s SurVaxM Improves Survival Time In Newly Diagn...

Mimivax’s SurVaxM Improves Survival Time In Newly Diagnosed Glioblastoma

  • havensmith

Is Paxalisib Better Than Temozolomide In The First-Line...

Paxalisib showed positive and promising results in the phase II trial. (Abs...

  • havensmith

With The Emergence of Next-Generation SERDs, Sanofi Mig...

With The Emergence of Next-Generation SERDs, Sanofi Might Hit The Mark

  • havensmith